Chemotherapy vs immunotherapy: how doctors compare them

Chemotherapy uses medicines that directly damage or stop the growth of cancer cells. Because some healthy cells also grow quickly, treatment can affect tissues such as hair follicles, the mouth, and bone marrow. Immunotherapy works by changing or strengthening selected immune responses so immune cells can recognise cancer more effectively. It does not suit every tumour, and its effect depends on features of the cancer and the person’s immune health.

A team may consider chemotherapy when the cancer is known to respond to cytotoxic medicines, when treatment needs to act across several tumour sites, or when reducing tumour size quickly is part of the plan. It may be used before surgery, after surgery, for control of advanced disease, or alongside another treatment. The exact drug combination is matched to the cancer type, previous treatment, blood counts, and kidney or liver function.

Immunotherapy may be considered when the cancer has features associated with benefit from immune treatment, or when the treatment plan calls for immune checkpoint blockade or another immune-based approach. Testing of tumour tissue or blood may help identify whether it is suitable. The clinician also reviews autoimmune conditions, organ function, medicines that suppress immunity, and any previous immune-related reaction.

Chemotherapy can cause tiredness, nausea, appetite changes, mouth soreness, hair loss, lowered blood-cell counts, and a higher risk of infection; the pattern varies by medicine. Immunotherapy can cause the immune system to inflame organs, leading to symptoms such as diarrhoea, rash, cough, breathlessness, thyroid changes, or liver abnormalities. Some immune effects need prompt treatment and can appear during therapy or after a dose. Report fever, breathing changes, severe diarrhoea, new weakness, or yellowing of the skin promptly.

Neither treatment is automatically the right next step. Surgery, radiotherapy, hormone treatment, targeted therapy, a different systemic medicine, active surveillance, or symptom-focused care may fit better. A cancer can also require a sequence of treatments rather than a single choice. If the disease has changed after treatment, new tissue or molecular testing may clarify the next option.

Your clinicians combine the cancer’s location and stage with biopsy findings, biomarker results, previous treatments, treatment goals, and your day-to-day health. They consider likely benefits alongside effects on blood counts, organs, fertility, work, and other priorities. Ask which result makes the recommended treatment appropriate, how response will be checked, which symptoms need an urgent call, and what the next option would be if the plan needs changing.